Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | The potential of targeting PAK6 in CML

Andrew Wu • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Andrew Wu, BS, MS, British Columbia Cancer Agency, Vancouver, Canada, comments on the rationale for targeting p21-activated kinase 6 (PAK6) in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrew Wu

1:49
The use of miRNAs as predictive biomarkers in CML
Andrew Wu • 22 Oct 2022
1:11
Gene knockdown strategies to investigate the properties of leukemic stem cells
Andrew Wu • 22 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals